Displaying 51 - 100 of 163 results
Released Company Title Industry Topic
11 Sep 2023
10:36 CEST
NYKODE THERAPEUTICS ASA Nykode Therapeutics to Present at H.C. Wainwright 25th Annual Global Investment Conference 20103010 Biotechnology Non-regulatory press releases
07 Sep 2023
16:34 CEST
NYKODE THERAPEUTICS ASA Nykode Therapeutics – Invitation to Capital Markets Day in New York on September 20, 2023 20103010 Biotechnology Non-regulatory press releases
05 Sep 2023
07:00 CEST
NYKODE THERAPEUTICS ASA Nykode Therapeutics Announces FDA Approval of IND for VB-C-04, a Trial of VB10.16 in HPV16-Positive Cervical Cancer 20103010 Biotechnology Non-regulatory press releases
23 Aug 2023
06:45 CEST
NYKODE THERAPEUTICS ASA Nykode Therapeutics - Quarterly report Q2 2023 20103010 Biotechnology Half yearly financial reports and audit reports/limited reviews
17 Aug 2023
08:30 CEST
NYKODE THERAPEUTICS ASA Nykode Therapeutics to announce financial results for the second quarter 2023 and host webcast presentation on August 23, 2023 20103010 Biotechnology Non-regulatory press releases
07 Jul 2023
17:01 CEST
NYKODE THERAPEUTICS ASA Grant of share options 20103010 Biotechnology Mandatory notification of trade primary insiders
03 Jul 2023
20:54 CEST
NYKODE THERAPEUTICS ASA Nykode Therapeutics – updated company presentation July 2023 20103010 Biotechnology Non-regulatory press releases
01 Jun 2023
06:45 CEST
NYKODE THERAPEUTICS ASA Nykode Therapeutics Announces Expansion of Clinical Collaboration with Roche to Evaluate VB10.16 in Combination with anti-PD-L1 in the next trial in Advanced Cervical Cancer 20103010 Biotechnology Non-regulatory press releases
30 May 2023
18:00 CEST
NYKODE THERAPEUTICS ASA Nykode Therapeutics to Present at Jefferies Healthcare Conference 20103010 Biotechnology Non-regulatory press releases
26 May 2023
16:46 CEST
NYKODE THERAPEUTICS ASA Grant of share options 20103010 Biotechnology Mandatory notification of trade primary insiders
12 May 2023
07:00 CEST
NYKODE THERAPEUTICS ASA Nykode Therapeutics - Quarterly report Q1 2023 20103010 Biotechnology Half yearly financial reports and audit reports/limited reviews
11 May 2023
11:10 CEST
NYKODE THERAPEUTICS ASA Nykode Therapeutics ASA - Minutes of Annual General Meeting 20103010 Biotechnology Additional regulated information required to be disclosed under the laws of a Member State
10 May 2023
17:25 CEST
NYKODE THERAPEUTICS ASA Disclosure of voting rights at AGM 20103010 Biotechnology Major shareholding notifications
08 May 2023
19:40 CEST
NYKODE THERAPEUTICS ASA Financial calendar 20103010 Biotechnology Additional regulated information required to be disclosed under the laws of a Member State
08 May 2023
19:40 CEST
NYKODE THERAPEUTICS ASA Nykode Therapeutics to announce financial results for the first quarter 2023 and host webcast presentation on May 12, 2023 20103010 Biotechnology Non-regulatory press releases
20 Apr 2023
07:00 CEST
NYKODE THERAPEUTICS ASA Nykode Therapeutics ASA - Notice of Annual General Meeting 20103010 Biotechnology Additional regulated information required to be disclosed under the laws of a Member State
19 Apr 2023
08:00 CEST
NYKODE THERAPEUTICS ASA Nykode Therapeutics - Annual Report 2022 20103010 Biotechnology Annual financial and audit Reports
18 Apr 2023
16:44 CEST
NYKODE THERAPEUTICS ASA Nykode Therapeutics announces positive final results from its Phase 2 trial of VB10.16 in combination with PD-L1 inhibitor atezolizumab in advanced cervical cancer 20103010 Biotechnology Inside information
28 Feb 2023
07:00 CET
NYKODE THERAPEUTICS ASA Nykode Therapeutics - Quarterly report 4Q 2022 20103010 Biotechnology Half yearly financial reports and audit reports/limited reviews
22 Feb 2023
13:00 CET
NYKODE THERAPEUTICS ASA Nykode Therapeutics to announce financial results for the fourth quarter 2022 and host webcast presentation on February 28, 2023 20103010 Biotechnology Non-regulatory press releases
13 Feb 2023
08:11 CET
NYKODE THERAPEUTICS ASA Nykode Therapeutics ASA – Flaggemelding Jan Haudemann-Andersen 20103010 Biotechnology Flagging
10 Feb 2023
06:45 CET
NYKODE THERAPEUTICS ASA Nykode Therapeutics Announces Collaboration with The GOG Foundation, Inc. to Conduct the VB-C-04 Trial in Advanced Cervical Cancer 20103010 Biotechnology Non-regulatory press releases
07 Feb 2023
13:00 CET
NYKODE THERAPEUTICS ASA Nykode Therapeutics to Present at SVB Securities Global Biopharma Conference 20103010 Biotechnology Non-regulatory press releases
01 Feb 2023
13:31 CET
NYKODE THERAPEUTICS ASA Registration of new share capital 20103010 Biotechnology Total number of voting rights and capital
25 Jan 2023
18:45 CET
NYKODE THERAPEUTICS ASA Exercise of warrants and related transactions by primary insiders - Mandatory notification of trade primary insiders
09 Jan 2023
17:45 CET
NYKODE THERAPEUTICS ASA Nykode Therapeutics - Presentation at the 41st Annual J.P. Morgan Healthcare Conference 20103010 Biotechnology Non-regulatory press releases
30 Dec 2022
09:25 CET
NYKODE THERAPEUTICS ASA Financial calendar 20103010 Biotechnology Additional regulated information required to be disclosed under the laws of a Member State
23 Dec 2022
11:00 CET
NYKODE THERAPEUTICS ASA Nykode Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference 20103010 Biotechnology Non-regulatory press releases
22 Dec 2022
12:43 CET
NYKODE THERAPEUTICS ASA Share capital increase from exercise of warrants 20103010 Biotechnology Total number of voting rights and capital
20 Dec 2022
16:11 CET
NYKODE THERAPEUTICS ASA Registration of new share capital 20103010 Biotechnology Total number of voting rights and capital
20 Dec 2022
06:45 CET
NYKODE THERAPEUTICS ASA Nykode announces expanded clinical development plan for its lead cancer vaccine VB10.16 in HPV16-positive cancers 20103010 Biotechnology Non-regulatory press releases
19 Dec 2022
06:45 CET
NYKODE THERAPEUTICS ASA Nykode Therapeutics and Richter-Helm BioLogics Announce Strategic Manufacturing Partnership 20103010 Biotechnology Non-regulatory press releases
18 Dec 2022
22:45 CET
NYKODE THERAPEUTICS ASA Exercise of warrants by primary insider, transactions by a primary insider and a close associate, and disclosure of large shareholding 20103010 Biotechnology Mandatory notification of trade primary insiders
06 Dec 2022
16:45 CET
NYKODE THERAPEUTICS ASA Nykode Therapeutics Announces Clinical Collaboration with MSD to Evaluate VB10.16 in Combination With KEYTRUDA® (pembrolizumab) in Patients with HPV16-Positive Head and Neck Cancer 20103010 Biotechnology Non-regulatory press releases
23 Nov 2022
07:00 CET
NYKODE THERAPEUTICS ASA Nykode Therapeutics - Quarterly report 3Q 2022 20103010 Biotechnology Half yearly financial reports and audit reports/limited reviews
16 Nov 2022
16:00 CET
NYKODE THERAPEUTICS ASA Nykode Therapeutics to announce financial results for the third quarter 2022 and host webcast presentation on November 23, 2022 20103010 Biotechnology Non-regulatory press releases
07 Nov 2022
16:30 CET
NYKODE THERAPEUTICS ASA Nykode Therapeutics presents additional efficacy analysis in Phase 2 study of VB10.16 in combination with atezolizumab in advanced cervical cancer 20103010 Biotechnology Non-regulatory press releases
07 Nov 2022
08:00 CET
NYKODE THERAPEUTICS ASA Nykode Therapeutics to present at two upcoming investor conferences in November 20103010 Biotechnology Non-regulatory press releases
28 Oct 2022
08:00 CEST
NYKODE THERAPEUTICS ASA Nykode Therapeutics to Present a Poster on Interim Results from the Pre-planned Interim Analysis from the C-02 trial with VB10.16 in advanced cervical patients at the European Society of Gynaecological Oncology’s 23rd Annual Meeting (ESGO 2022) 20103010 Biotechnology Non-regulatory press releases
26 Oct 2022
16:30 CEST
NYKODE THERAPEUTICS ASA Nykode Therapeutics Announces Presentation of Positive Immunogenicity Results from Phase 1/2a Study of VB10.NEO, an Individualized Therapeutic Cancer Vaccine, at the Neoantigen-Based Therapies Summit 20103010 Biotechnology Non-regulatory press releases
24 Oct 2022
17:58 CEST
NYKODE THERAPEUTICS ASA Mandatory notification of intra group transfer of shares by primary insider’s related party 20103010 Biotechnology Mandatory notification of trade primary insiders
27 Sep 2022
06:45 CEST
NYKODE THERAPEUTICS ASA Nykode Therapeutics Announces Positive Results from the Phase 1/2 Open Label, Dose Escalation Trial of its T Cell Focused SARS-CoV-2 Vaccine Candidate 20103010 Biotechnology Inside information
09 Sep 2022
17:00 CEST
NYKODE THERAPEUTICS ASA Nykode Therapeutics to present at H.C. Wainwright 24th Annual Global Investment Conference 20103010 Biotechnology Non-regulatory press releases
08 Sep 2022
07:00 CEST
NYKODE THERAPEUTICS ASA Nykode Therapeutics to be included in the Oslo Børs Benchmark Index (OSEBX) and the Oslo Børs Mutual Fund Index (OSEFX) 20103010 Biotechnology Non-regulatory press releases
26 Aug 2022
16:44 CEST
NYKODE THERAPEUTICS ASA Nykode Therapeutics ASA - Mandatory notification for close associate of primary insider 20103010 Biotechnology Mandatory notification of trade primary insiders
24 Aug 2022
07:00 CEST
NYKODE THERAPEUTICS ASA Nykode Therapeutics - Quarterly report 2Q 2022 20103010 Biotechnology Half yearly financial reports and audit reports/limited reviews
22 Aug 2022
06:45 CEST
NYKODE THERAPEUTICS ASA Nykode Therapeutics to announce financial results for the first half of 2022 and host webcast presentation on August 24, 2022 20103010 Biotechnology Non-regulatory press releases
04 Jul 2022
20:50 CEST
NYKODE THERAPEUTICS ASA Grant of Share Options 20103010 Biotechnology Mandatory notification of trade primary insiders
15 Jun 2022
15:54 CEST
NYKODE THERAPEUTICS ASA Nykode Therapeutics - approval and publication of prospectus and admission to trading on the Oslo Stock Exchange’s main list 20103010 Biotechnology Prospectus / admission document
13 Jun 2022
10:32 CEST
NYKODE THERAPEUTICS ASA Oslo Børs - Decision on admission to trading – Nykode Therapeutics ASA 20103010 Biotechnology Additional regulated information required to be disclosed under the laws of a Member State